Title : Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.

Pub. Date : 2022

PMID : 35114682






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: De-escalation therapy omitting anthracycline has been generally adopted for patients with HER2-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC) setting. Anthracyclines erb-b2 receptor tyrosine kinase 2 Homo sapiens